|
12/30/11
CorMedix Provides Year End 2011 Update
11/28/11
CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy to Board of Directors
11/10/11
CorMedix Reports Third Quarter 2011 Results
10/7/11
CorMedix to Host Conference Call on Recent Developments
9/30/11
CorMedix Announces Strategic Changes
9/29/11
CorMedix Announces FDA Designation for Neutrolin (CRMD003)
9/7/11
CorMedix to Present at the Rodman & Renshaw Annual Global Investment Conference
9/6/11
CorMedix Announces Amended Agreement for CRMD001
8/12/11
CorMedix Announces Appointment of Steven W. Lefkowitz to Board of Directors
8/9/11
CorMedix Reports Second Quarter 2011 Results
7/7/11
CorMedix Submits Design Dossier for Neutrolin® (CRMD003) to Start European Approval Process
6/23/11
CorMedix Provides Regulatory Update for CRMD003 (Neutrolin®)
6/21/11
CorMedix Announces SPA Agreement with FDA For Phase 3 Trial in the Prevention of Contrast-Induced Acute Kidney Injury Study with CRMD001 (A Proprietary Formulation of Deferiprone)
6/14/11
Cormedix Annouces Successful Completion of Patient Recruitment in Phase ll Contrast-Induced Acute Kidney Injury Study with CRMD0011 (A Proprietary Formulation of Deferiprone)
5/10/2011
CorMedix Reports First Quarter 2011 Financial Results
3/31/2011
CorMedix Announces Interim Analysis & Clinical Update for Phase ll Study of CRMD001 ( A Proprietary Formulation of Deferiprone )
3/11/2011
CorMedix Reports Year End 2010 Financial Results
3/2/2011
CorMedix Appoints Mark A. Klausner, M.D. as Chief Medical Officer
2/8/2011
CorMedix to Present at 13th Annual BIO CEO and Investor Conference
1/4/2011
CorMedix Provides Year End Summary of 2010 Achievements
11/15/2010
CorMedix to Present at the Maxim Group Growth Conference
11/9/2010
CorMedix Reports Third Quarter 2010 Results and Provides Business Update
11/3/2010
CorMedix Awarded Grants from Federal Qualifying Therapeutic Discovery Project Program
9/28/2010
CorMedix to Present at BIO Investor Forum Conference
9/3/2010
CorMedix to Present at the Rodman & Renshaw Annual Global Investment Conference
8/12/2010
CorMedix Reports Second Quarter 2010 Results
8/10/2010
CorMedix Announces Appointment of Key Positions
6/29/2010
CorMedix Added to Russell Microcap® Index
6/25/2010
CorMedix Doses First Patient in Phase II Clinical Trial of CRMD-001
5/13/2010
Units Issued in CorMedix IPO to Separate on May 13, 2010
5/11/2010
CorMedix Inc. Announces First Quarter 2010 Financial Results
4/20/2010
United States Patent Issued for CorMedix’s Neutrolin® to Prevent Catheter Related Bloodstream Infections (CRBI) and Clotting in Hemodialysis Catheters
4/8/2010
CorMedix Rings Closing Bell (Archive)
|
